TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00473486
Drug: pemetrexed, carboplatin, sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1
Study: NCT00473486
Drug: pemetrexed, carboplatin, placebo
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
Study: NCT01355081
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine tablets
Study: NCT01647646
Drug: Seretide
Normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Study: NCT01288664
Drug: ADVAGRAF
Normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
Study: NCT00276757
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02226458
Drug: EPI-743
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01597401
Drug: Aes-103
Normalized name: Ae-turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Study: NCT01597401
Drug: Aes-103
Normalized name: Ae-turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Study: NCT00186706
Drug: Selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01597401
Drug: Aes-103
Normalized name: Ae-turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Study: NCT00272064
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
Study: NCT00272064
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
Study: NCT00499642
Drug: Lecozotan SR
Normalized name: Lecozotan
DrugBank: Lecozotan (DB12540)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00499642
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000482
Drug: estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000482
Drug: clofibrate clofibrate
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000482
Drug: dextrothyroxine sodium
Normalized name: dextrothyroxine sodium
DrugBank: Dextrothyroxine (DB00509)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01597401
Drug: Aes-103
Normalized name: Ae-turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
Study: NCT00000482
Drug: niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03916094
Drug: HLX22
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
Study: NCT01790568
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
Study: NCT01790568
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02344784
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
Study: NCT04008784
Drug: Crisaborole 2% Topical Application Ointment [EUCRISA]
Normalized name: Crisaborole 2% Topical application Ointment [EUCRISA]
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ointment
Study: NCT04008784
Drug: Triamcinolone Acetonide 0.1% Ointment
Normalized name: DIMETHICONE 5% CREAM/TRIAMCINOLONE ACETONIDE 0.1% OINTMENT,KIT
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Corticosteroid
Study: NCT00272064
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg b.i.d, since the qualification phase, oral
Study: NCT01931787
Drug: 6,8-bis(benzylthio)octanoic acid
Normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01621165
Drug: Addition of prazosin to usual care (add-on study)
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Study: NCT04510688
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observation of treatment with Cabozantinib
Study: NCT04166383
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
Study: NCT03095222
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
Study: NCT01215565
Drug: Sutent
Normalized name: Sutent
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
Study: NCT00545402
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
Study: NCT00085696
Drug: VELCADE and rituximab
Normalized name: Velcade
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04063358
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lucentis 0.5 MG Per 0.05 ML Injection
Study: NCT00223262
Drug: Lamotrigine (Drug)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01546883
Drug: Dabigatran etexilate (Pradaxa)
Normalized name: dabigatran etexilate Oral Pellet [Pradaxa]
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg bid or 75mg bid for a period of one year
Study: NCT01660321
Drug: spinosad
Normalized name: Spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
Study: NCT03975036
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride Capsules
Study: NCT03975036
Drug: pd-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumabinjection
Study: NCT05084001
Drug: silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application of the agent on tooth surface
Study: NCT05084001
Drug: sodium fluoride varnish
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application of the agent on tooth surface
Study: NCT01806805
Drug: zonegran
Normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04926428
Drug: tPA
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selectively catheter thrombolysis with alteplase in each main pulmonary
Study: NCT01624259
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01624259
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02848950
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Supplementation of the study group with Metformin till the day of pregnancy confirmation
Study: NCT02747953
Drug: Gilotrif
Normalized name: Gilotrif
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
Study: NCT03100071
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
Study: NCT00314353
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.
Study: NCT00314353
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2 IV Day 1 every 21 days for eight cycles
Study: NCT00314353
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 IV Day 1 every 21 days for eight cycles
Study: NCT00930839
Drug: Niacin and aspirin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Niacin, 325 mg aspirin
Study: NCT01855451
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01855451
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00407589
Drug: BOL-303224-A
Normalized name: Bol 303213x tosylate
DrugBank: ESK981 (DB18155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
Study: NCT00448175
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04020939
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
Study: NCT03919929
Drug: Semaglutide 3mg and 7mg [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily oral tablet of semaglutide for 4 months
Study: NCT00041275
Drug: megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04332627
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
Study: NCT04332627
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
Study: NCT02467621
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg x 1 daily intravenously from ICU admission to ICU discharge
Study: NCT02486848
Drug: 5% Topical Minoxidil Solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% Topical Minoxidil Solution
Study: NCT02486848
Drug: 15% Topical Minoxidil Solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15% Topical Minoxidil Solution
Study: NCT00577109
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg iv on day 1 of each 2 week cycle
Study: NCT00577109
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180mg/m2 iv on day 1 of each 2 week cycle
Study: NCT00577109
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
Study: NCT00878111
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period.
Study: NCT00694551
Drug: Poly IC-LC
Normalized name: poly ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
Study: NCT03030196
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NaCl 0.9% injection is used as placebo
Study: NCT03255148
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syntocinon nasal spray
Study: NCT00183794
Drug: Docetaxel and Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
Study: NCT01228409
Drug: Acitretin 17.5 mg/day
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
Study: NCT00229073
Drug: dapoxetine
Normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00145522
Drug: Tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,5 mg/day for 12 cycles of 28 days
Study: NCT04076254
Drug: Fluid
Normalized name: IV fluid
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer Lactate
Study: NCT01817907
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive trazodone during one of their treatment arm studies
Study: NCT03420079
Drug: FCN-411 Dose-expansion
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Study: NCT02170675
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02170675
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02000596
Drug: Trastuzumab plus Pertuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02000596
Drug: Hormonal Therapy with Anastrozole and Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
Study: NCT02000596
Drug: Chemotherapy with Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03161288
Drug: KY1005
Normalized name: Immunoglobulin g4 (235-proline,242-glutamic acid), anti-(human ox40 ligand) (human monoclonal ky1005-2d10 .gamma.4-chain), disulfide with human monoclonal ky1005-2d10 .kappa.-chain, dimer
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human anti-OX40 ligand monoclonal antibody
Study: NCT01826851
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.
Study: NCT00478465
Drug: valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01817283
Drug: Triptolide
Normalized name: Triptolide
DrugBank: Triptolide (DB12025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Study: NCT01817283
Drug: cART
Normalized name: CARTON
DrugBank: Carteolol (DB00521)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study: NCT00622284
Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
Normalized name: edaravone
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo tablets once daily
Study: NCT00622284
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, once daily in the morning for 104 weeks
Study: NCT00622284
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
Study: NCT01717287
Drug: Raltegravir Film-coated Tablet
Normalized name: raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01717287
Drug: Raltegravir Chewable Tablet
Normalized name: raltegravir Chewable Tablet
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02425579
Drug: Inhaled Carbon Monoxide at 100ppm (4 participants)
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
Study: NCT02425579
Drug: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days
Study: NCT02425579
Drug: Inhaled Carbon Monoxide at 200ppm (4 participants)
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
Study: NCT02425579
Drug: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days
Study: NCT02242201
Drug: PNB Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion
Study: NCT02242201
Drug: PAI Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection
Study: NCT02242201
Drug: PAI liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection
Study: NCT04200417
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.